The dissolution rate of the Biopharmaceutical Classification System (BSC) Class II compounds (low water solubility and high permeability) is one of the major problems with formulating and the bioavailability. Recently, enhancement of the oral bioavailability of the BSC Class II compounds by nanoemulsion drug delivery system has been developed to overcome the major drawbacks associated with conventional drug delivery systems and enhance the therapeutic efficacy of the drug and minimize adverse effect and toxic reactions.
From the perspective of the dosage form, pellets loaded with dried nanoemulsions have some desired advantages offering great attraction to the pharmaceutical industry. The pellets have improved the appearance with fine pharmaceutical elegance, they can decrease the risk of dose dumping and local mucosal irritation, avoid powder dusting in the pharmaceutical industries, and also their larger surface area enables better distribution in case of immediate release products. Furthermore, pellets disperse freely in the gastrointestinal tract and invariably maximize drug absorption with a subsequent reduction in peak plasma fluctuations; as a result they minimize potential side effects without lowering drug bioavailability. Moreover, reduction of intra- and inter-patient variability of plasma profiles is achieved by reducing overall transit time.
The combination of nanoemulsions delivery systems and extrusion spheronization can be manufactured economically for commercial applications.
Recommended for you